PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
9.15%
Growth of 9.15% versus flat Medical - Pharmaceuticals revenue. Walter Schloss would verify growth quality.
9.97%
Cost growth exceeding 1.5x Medical - Pharmaceuticals median of 0.93%. Jim Chanos would check for structural cost disadvantages.
5.86%
Gross profit growth exceeding 1.5x Medical - Pharmaceuticals median of 0.42%. Joel Greenblatt would investigate competitive advantages.
-3.01%
Margin decline while Medical - Pharmaceuticals median is -0.05%. Seth Klarman would investigate competitive position.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
G&A reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate efficiency gains.
-100.00%
Marketing expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive implications.
-2.72%
Other expenses reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
4.32%
Operating expenses growth exceeding 1.5x Medical - Pharmaceuticals median of 0.32%. Jim Chanos would check for waste.
9.01%
Total costs growth exceeding 1.5x Medical - Pharmaceuticals median of 0.36%. Jim Chanos would check for waste.
5.88%
Interest expense change of 5.88% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify control.
-2.38%
D&A reduction while Medical - Pharmaceuticals median is -0.60%. Seth Klarman would investigate efficiency.
7.44%
EBITDA growth exceeding 1.5x Medical - Pharmaceuticals median of 3.27%. Joel Greenblatt would investigate advantages.
-1.57%
EBITDA margin decline while Medical - Pharmaceuticals median is 2.38%. Seth Klarman would investigate causes.
12.93%
Operating income growth exceeding 1.5x Medical - Pharmaceuticals median of 5.21%. Joel Greenblatt would investigate advantages.
3.46%
Operating margin growth 50-75% of Medical - Pharmaceuticals median of 5.86%. Guy Spier would scrutinize operations.
11.38%
Other expenses growth below 50% of Medical - Pharmaceuticals median of 38.95%. Joel Greenblatt would investigate efficiency.
12.82%
Pre-tax income growth exceeding 1.5x Medical - Pharmaceuticals median of 6.51%. Joel Greenblatt would investigate advantages.
3.36%
Pre-tax margin growth near Medical - Pharmaceuticals median of 3.36%. Charlie Munger would verify industry dynamics.
204.58%
Tax expense growth exceeding 1.5x Medical - Pharmaceuticals median of 10.61%. Jim Chanos would check for issues.
-13.39%
Net income decline while Medical - Pharmaceuticals median is 3.20%. Seth Klarman would investigate causes.
-20.65%
Net margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-13.40%
EPS decline while Medical - Pharmaceuticals median is 4.00%. Seth Klarman would investigate causes.
-13.40%
Diluted EPS decline while Medical - Pharmaceuticals median is 4.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.